<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sat, 26 Aug 2023 20:07:16 +0000</lastbuilddate>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Interatrial shunt devices for heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37626203/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Aug 25. doi: 10.1038/s41569-023-00923-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37626203/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37626203</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00923-w>10.1038/s41569-023-00923-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37626203</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Interatrial shunt devices for heart failure</dc:title>
<dc:identifier>pmid:37626203</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00923-w</dc:identifier>
</item>
<item>
<title>Atrial fibrillation progression after cryoablation versus radiofrequency ablation: the CIRCA-DOSE trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37624879/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Catheter ablation of paroxysmal AF using radiofrequency energy was associated with fewer patients developing persistent AF on follow-up.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad572. doi: 10.1093/eurheartj/ehad572. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Atrial fibrillation (AF) is a chronic, progressive disorder. Persistent forms of AF are associated with increased rates of thromboembolism, heart failure, and death. Catheter ablation modifies the pathogenic mechanism of AF progression. No randomized studies have evaluated the impact of the ablation energy on progression to persistent atrial tachyarrhythmia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: 346 patients with drug-refractory paroxysmal AF were enrolled and randomized to contact-force guided radiofrequency ablation (CF-RF ablation, n = 115), 4-minute cryoballoon ablation (CRYO-4, n = 115), or 2-minute cryoballoon ablation (CRYO-2, n = 116). Implantable cardiac monitors placed at study entry were used for follow-up. The main outcome was the first episode of persistent atrial tachyarrhythmia. Secondary outcomes included atrial tachyarrhythmia recurrence, and arrhythmia burden on implantable monitor.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At a median of 944.0 (interquartile range [IQR], 612.5-1104) days, 0 of 115 patients (0.0%) randomly assigned to CF-RF, 8 of 115 patients (7.0%) assigned to CRYO-4, and 5 of 116 patients (4.3%) assigned to CRYO-2 experienced an episode of persistent atrial tachyarrhythmia (P = 0.03). A documented recurrence of any atrial tachyarrhythmia ≥30 seconds occurred in 56.5%, 53.9%, and 62.9% of those randomised to CF-RF, CRYO-4, and CRYO-2, respectively (P = 0.65). Compared to the pre-ablation monitoring period, AF burden was reduced by a median of 99.5% (IQR 94.0-100.0%) with CF-RF, 99.9% (IQR 93.3-100.0%) with CRYO-4, and 99.1% (IQR 87.0-100.0%) with CRYO-2 (P = 0.38).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Catheter ablation of paroxysmal AF using radiofrequency energy was associated with fewer patients developing persistent AF on follow-up.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37624879/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37624879</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad572>10.1093/eurheartj/ehad572</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37624879</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jason G Andrade</dc:creator>
<dc:creator>Marc W Deyell</dc:creator>
<dc:creator>Paul Khairy</dc:creator>
<dc:creator>Jean Champagne</dc:creator>
<dc:creator>Peter Leong-Sit</dc:creator>
<dc:creator>Paul Novak</dc:creator>
<dc:creator>Lawrence Sterns</dc:creator>
<dc:creator>Jean-Francois Roux</dc:creator>
<dc:creator>John Sapp</dc:creator>
<dc:creator>Richard Bennett</dc:creator>
<dc:creator>Matthew Bennett</dc:creator>
<dc:creator>Nathaniel Hawkins</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Laurent Macle</dc:creator>
<dc:creator>CIRCA-DOSE Study Investigators</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation progression after cryoablation versus radiofrequency ablation: the CIRCA-DOSE trial</dc:title>
<dc:identifier>pmid:37624879</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad572</dc:identifier>
</item>
<item>
<title>TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37624856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad585. doi: 10.1093/eurheartj/ehad585. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Benefit of tricuspid regurgitation (TR) correction and timing of intervention are unclear. This study aimed to compare survival rates after surgical or transcatheter intervention to conservative management according to TR clinical stage as assessed using the TRI-SCORE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: 2,413 patients with severe isolated functional TR were enrolled in TRIGISTRY (1217 conservatively managed, 551 isolated tricuspid valve surgery and 645 transcatheter valve repair). The primary endpoint was survival at 2 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The TRI-SCORE was low (≤3) in 32%, intermediate (4-5) in 33% and high (≥6) in 35%. A successful correction was achieved in 97% and 65% of patients in the surgical and transcatheter groups, respectively. Survival rates decreased with the TRI-SCORE in the three treatment groups (all P &lt; 0.0001). In the low TRI-SCORE category, survival rates were higher in the surgical and transcatheter groups than in the conservative management group (93%, 87% and 79%, respectively; P = 0.0002). In the intermediate category, no significant difference between groups was observed overall (80%, 71% and 71%, respectively; P = 0.13) but benefit of the intervention became significant when the analysis was restricted to patients with successful correction (80%, 81% and 71%, respectively; P = 0.009). In the high TRI-SCORE category, survival was similar between groups even when restricted to patients with successful correction (61%, 68% and 58% respectively, P = 0.08).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37624856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37624856</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad585>10.1093/eurheartj/ehad585</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37624856</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Julien Dreyfus</dc:creator>
<dc:creator>Xavier Galloo</dc:creator>
<dc:creator>Maurizio Taramasso</dc:creator>
<dc:creator>Gregor Heitzinger</dc:creator>
<dc:creator>Giovanni Benfari</dc:creator>
<dc:creator>Karl-Patrick Kresoja</dc:creator>
<dc:creator>Fernando Juarez-Casso</dc:creator>
<dc:creator>Hazem Omran</dc:creator>
<dc:creator>Yohann Bohbot</dc:creator>
<dc:creator>Christos Iliadis</dc:creator>
<dc:creator>Giulio Russo</dc:creator>
<dc:creator>Yan Topilsky</dc:creator>
<dc:creator>Marcel Weber</dc:creator>
<dc:creator>Luis Nombela-Franco</dc:creator>
<dc:creator>Alessandra Sala</dc:creator>
<dc:creator>Andrea Eixerés-Esteve</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Jean-François Obadia</dc:creator>
<dc:creator>Rodrigo Estevez Loureiro</dc:creator>
<dc:creator>Elisabeth Riant</dc:creator>
<dc:creator>Erwan Donal</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>Luigi Badano</dc:creator>
<dc:creator>Thierry Le Tourneau</dc:creator>
<dc:creator>Augustin Coisne</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Azeem Latib</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Jose Luis Zamorano</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Rebecca Hahn</dc:creator>
<dc:creator>John Webb</dc:creator>
<dc:creator>Denisa Muraru</dc:creator>
<dc:creator>Mohammed Nejjari</dc:creator>
<dc:creator>Vincent Chan</dc:creator>
<dc:creator>Michele De Bonis</dc:creator>
<dc:creator>Manuel Carnero-Alcazar</dc:creator>
<dc:creator>Georg Nickenig</dc:creator>
<dc:creator>Roman Pfister</dc:creator>
<dc:creator>Christophe Tribouilloy</dc:creator>
<dc:creator>Volker Rudolph</dc:creator>
<dc:creator>Juan Crestanello</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Philipp Bartko</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:creator>Jeroen Bax</dc:creator>
<dc:creator>Maurice Enriquez-Sarano</dc:creator>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:creator>TRIGISTRY investigators</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation</dc:title>
<dc:identifier>pmid:37624856</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad585</dc:identifier>
</item>
<item>
<title>Adverse outcomes in patients with atrial fibrillation: how previous successes can unmask new challenges</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37624615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad575. doi: 10.1093/eurheartj/ehad575. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37624615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37624615</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad575>10.1093/eurheartj/ehad575</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37624615</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Pascal B Meyre</dc:creator>
<dc:creator>David Conen</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Adverse outcomes in patients with atrial fibrillation: how previous successes can unmask new challenges</dc:title>
<dc:identifier>pmid:37624615</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad575</dc:identifier>
</item>
<item>
<title>Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37624589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: After AF diagnosis, cardio/cerebrovascular mortality and hospitalisation has declined, whilst hospitalisation for non-cardio/cerebrovascular disease has increased.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad571. doi: 10.1093/eurheartj/ehad571. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Reports of outcomes after atrial fibrillation (AF) diagnosis are conflicting. The aim of this study was to investigate mortality and hospitalisation rates following AF diagnosis over time, by cause, and by patient features.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Individuals aged ≥16 years with a first diagnosis of AF were identified from the UK Clinical Practice Research Datalink-GOLD dataset from Jan 1, 2001 to Dec 31, 2017. The primary outcomes were all-cause and cause-specific mortality and hospitalisation at 1 year following diagnosis. Poisson regression was used to calculate rate ratios (RRs) for mortality and incidence rate ratios (IRRs) for hospitalisation and 95% confidence intervals (CIs) comparing 2001/02 and 2016/17, adjusted for age, sex, region, socioeconomic status and 18 major comorbidities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 72 412 participants, mean (SD) age was 75.6 (12.4) years and 44 762 (61.8%) had ≥3 comorbidities. All-cause mortality declined (RR 2016/17 vs 2001/02 0.72; 95% CI 0.65-0.80), with large declines for cardiovascular (RR 0.46; 95% CI 0.37-0.58) and cerebrovascular mortality (RR 0.41; 95% CI 0.29-0.60) but not for non-cardio/cerebrovascular causes of death (RR 0.91; 95% CI 0.80-1.04). By 2016/17 deaths from dementia (67, 8.0%), outstripped deaths from acute myocardial infarction, heart failure and acute stroke combined (56, 6.7%, p &lt; 0.001). Overall hospitalisation rates increased (IRR 2016/17 vs 2001/02 1.17; 95% CI, 1.13-1.22), especially for non-cardio/cerebrovascular causes (IRR 1.42; 95% CI 1.39-1.45). Older, more deprived, and hospital-diagnosed AF patients experienced higher event rates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: After AF diagnosis, cardio/cerebrovascular mortality and hospitalisation has declined, whilst hospitalisation for non-cardio/cerebrovascular disease has increased.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37624589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37624589</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad571>10.1093/eurheartj/ehad571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37624589</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jianhua Wu</dc:creator>
<dc:creator>Ramesh Nadarajah</dc:creator>
<dc:creator>Yoko M Nakao</dc:creator>
<dc:creator>Kazuhiro Nakao</dc:creator>
<dc:creator>Chris Wilkinson</dc:creator>
<dc:creator>J Campbell Cowan</dc:creator>
<dc:creator>A John Camm</dc:creator>
<dc:creator>Chris P Gale</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation</dc:title>
<dc:identifier>pmid:37624589</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad571</dc:identifier>
</item>
<item>
<title>Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37624364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 25. doi: 10.1161/CIRCULATIONAHA.123.065448. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37624364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37624364</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065448>10.1161/CIRCULATIONAHA.123.065448</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37624364</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Adrian Wlodarczak</dc:creator>
<dc:creator>Ralph Tölg</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Henning Kelbæk</dc:creator>
<dc:creator>Jacek Legutko</dc:creator>
<dc:creator>Stefano Galli</dc:creator>
<dc:creator>Matthieu Godin</dc:creator>
<dc:creator>Gabor G Toth</dc:creator>
<dc:creator>Thibault Lhermusier</dc:creator>
<dc:creator>Benjamin Honton</dc:creator>
<dc:creator>Peter Laurenz Dietrich</dc:creator>
<dc:creator>Francis Stammen</dc:creator>
<dc:creator>Bert Ferdinande</dc:creator>
<dc:creator>Johanne Silvain</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>Guillaume Cayla</dc:creator>
<dc:creator>Bioflow-DAPT Investigators</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial</dc:title>
<dc:identifier>pmid:37624364</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065448</dc:identifier>
</item>
<item>
<title>Acetazolamide for Acute Heart Failure: Is ADVOR a Riddle Wrapped in a Mystery Inside an Enigma?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37623429/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad560. doi: 10.1093/eurheartj/ehad560. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37623429/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37623429</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad560>10.1093/eurheartj/ehad560</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37623429</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Héctor Bueno</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acetazolamide for Acute Heart Failure: Is ADVOR a Riddle Wrapped in a Mystery Inside an Enigma?</dc:title>
<dc:identifier>pmid:37623429</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad560</dc:identifier>
</item>
<item>
<title>Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure: The ADVOR Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37623428/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Acetazolamide is associated with a higher rate of successful decongestion across the entire range of renal function with more pronounced effects regarding natriuresis and diuresis in patients with a lower eGFR. While WRF occurred more frequently with acetazolamide, this was not associated with adverse clinical outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad557. doi: 10.1093/eurheartj/ehad557. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In the ADVOR trial, acetazolamide improved decongestion in acute decompensated heart failure (ADHF). Whether the beneficial effects of acetazolamide are consistent across the entire range of renal function remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a prespecified analysis of the ADVOR trial that randomized 519 patients with ADHF to intravenous acetazolamide or matching placebo on top of intravenous loop diuretics. The main endpoints of decongestion, diuresis, natriuresis and clinical outcomes are assessed according to baseline renal function. Changes in renal function are evaluated between treatment arms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: On admission, median estimated glomerular filtration rate (eGFR) was 40 (30-52) mL/min/1.73 m². Acetazolamide consistently increased the likelihood of decongestion across the entire spectrum of eGFR (p-interaction=0.977). Overall, natriuresis and diuresis were higher with acetazolamide, with a higher treatment effect for patients with low eGFR (both p-interaction &lt;0.007). Acetazolamide was associated with a higher incidence of worsening renal function (WRF) (rise in creatinine ≥0.3 mg/dL) during the treatment period (40.5% vs. 18.9%; p&lt;0.001), but there was no difference in creatinine after 3 months (p=0.565). This was not associated with a higher incidence of heart failure hospitalizations and mortality (p-interaction=0.467). However, decongestion at discharge was associated with a lower incidence of adverse clinical outcomes irrespective of the onset of WRF (p-interaction=0.805).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Acetazolamide is associated with a higher rate of successful decongestion across the entire range of renal function with more pronounced effects regarding natriuresis and diuresis in patients with a lower eGFR. While WRF occurred more frequently with acetazolamide, this was not associated with adverse clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS.GOV IDENTIFIER: NCT03505788.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37623428/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37623428</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad557>10.1093/eurheartj/ehad557</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37623428</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Evelyne Meekers</dc:creator>
<dc:creator>Jeroen Dauw</dc:creator>
<dc:creator>Pieter Martens</dc:creator>
<dc:creator>Sebastiaan Dhont</dc:creator>
<dc:creator>Frederik H Verbrugge</dc:creator>
<dc:creator>Petra Nijst</dc:creator>
<dc:creator>Jozine M Ter Maaten</dc:creator>
<dc:creator>Kevin Damman</dc:creator>
<dc:creator>Alexandre Mebazaa</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Frank Ruschitzka</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Matthias Dupont</dc:creator>
<dc:creator>Wilfried Mullens</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure: The ADVOR Trial</dc:title>
<dc:identifier>pmid:37623428</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad557</dc:identifier>
</item>
<item>
<title>2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37622666/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad195. doi: 10.1093/eurheartj/ehad195. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37622666/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37622666</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad195>10.1093/eurheartj/ehad195</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37622666</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Theresa A McDonagh</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Marianna Adamo</dc:creator>
<dc:creator>Roy S Gardner</dc:creator>
<dc:creator>Andreas Baumbach</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Haran Burri</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Jelena Čelutkienė</dc:creator>
<dc:creator>Ovidiu Chioncel</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>Maria Generosa Crespo-Leiro</dc:creator>
<dc:creator>Dimitrios Farmakis</dc:creator>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>Stephane Heymans</dc:creator>
<dc:creator>Arno W Hoes</dc:creator>
<dc:creator>Tiny Jaarsma</dc:creator>
<dc:creator>Ewa A Jankowska</dc:creator>
<dc:creator>Mitja Lainscak</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Alexander R Lyon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Alexandre Mebazaa</dc:creator>
<dc:creator>Richard Mindham</dc:creator>
<dc:creator>Claudio Muneretto</dc:creator>
<dc:creator>Massimo Francesco Piepoli</dc:creator>
<dc:creator>Susanna Price</dc:creator>
<dc:creator>Giuseppe M C Rosano</dc:creator>
<dc:creator>Frank Ruschitzka</dc:creator>
<dc:creator>Anne Kathrine Skibelund</dc:creator>
<dc:creator>ESC Scientific Document Group</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure</dc:title>
<dc:identifier>pmid:37622666</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad195</dc:identifier>
</item>
<item>
<title>2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37622663/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad192. doi: 10.1093/eurheartj/ehad192. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37622663/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37622663</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad192>10.1093/eurheartj/ehad192</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37622663</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Nikolaus Marx</dc:creator>
<dc:creator>Massimo Federici</dc:creator>
<dc:creator>Katharina Schütt</dc:creator>
<dc:creator>Dirk Müller-Wieland</dc:creator>
<dc:creator>Ramzi A Ajjan</dc:creator>
<dc:creator>Manuel J Antunes</dc:creator>
<dc:creator>Ruxandra M Christodorescu</dc:creator>
<dc:creator>Carolyn Crawford</dc:creator>
<dc:creator>Emanuele Di Angelantonio</dc:creator>
<dc:creator>Björn Eliasson</dc:creator>
<dc:creator>Christine Espinola-Klein</dc:creator>
<dc:creator>Laurent Fauchier</dc:creator>
<dc:creator>Martin Halle</dc:creator>
<dc:creator>William G Herrington</dc:creator>
<dc:creator>Alexandra Kautzky-Willer</dc:creator>
<dc:creator>Ekaterini Lambrinou</dc:creator>
<dc:creator>Maciej Lesiak</dc:creator>
<dc:creator>Maddalena Lettino</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>Wilfried Mullens</dc:creator>
<dc:creator>Bianca Rocca</dc:creator>
<dc:creator>Naveed Sattar</dc:creator>
<dc:creator>ESC Scientific Document Group</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes</dc:title>
<dc:identifier>pmid:37622663</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad192</dc:identifier>
</item>
<item>
<title>Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37622660/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>Imaging plays an integral role in all aspects of managing heart disease and cardiac imaging is a core competency of cardiologists. The adequate delivery of cardiac imaging services requires expertise in both imaging methodology - with specific adaptations to imaging of the heart - as well as intricate knowledge of heart disease. The European Society of Cardiology (ESC) and the European Association of Cardiovascular Imaging (EACVI) of the ESC have developed and implemented a successful education...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad578. doi: 10.1093/eurheartj/ehad578. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Imaging plays an integral role in all aspects of managing heart disease and cardiac imaging is a core competency of cardiologists. The adequate delivery of cardiac imaging services requires expertise in both imaging methodology - with specific adaptations to imaging of the heart - as well as intricate knowledge of heart disease. The European Society of Cardiology (ESC) and the European Association of Cardiovascular Imaging (EACVI) of the ESC have developed and implemented a successful education and certification programme for all cardiac imaging modalities. This programme equips cardiologists to provide high quality competency-based cardiac imaging services ensuring they are adequately trained and competent in the entire process of cardiac imaging, from the clinical indication via selecting the best imaging test to answer the clinical question, to image acquisition, analysis, interpretation, storage, repository, and results dissemination. This statement emphasizes the need for competency-based cardiac imaging delivery which is key to optimal, effective and efficient, patient care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37622660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37622660</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad578>10.1093/eurheartj/ehad578</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37622660</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mark Westwood</dc:creator>
<dc:creator>Ana G Almeida</dc:creator>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:creator>Santo Dellegrottaglie</dc:creator>
<dc:creator>Kevin F Fox</dc:creator>
<dc:creator>Luna Gargani</dc:creator>
<dc:creator>Kurt Huber</dc:creator>
<dc:creator>Pál Maurovich-Horvat</dc:creator>
<dc:creator>Jose L Merino</dc:creator>
<dc:creator>Richard Mindham</dc:creator>
<dc:creator>Denisa Muraru</dc:creator>
<dc:creator>Lis Neubeck</dc:creator>
<dc:creator>Robin Nijveldt</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>Gianluca Pontone</dc:creator>
<dc:creator>Susanna Price</dc:creator>
<dc:creator>Giuseppe M C Rosano</dc:creator>
<dc:creator>Alexia Rossi</dc:creator>
<dc:creator>Leyla Elif Sade</dc:creator>
<dc:creator>Jeanette Schulz-Menger</dc:creator>
<dc:creator>Franz Weidinger</dc:creator>
<dc:creator>Stephan Achenbach</dc:creator>
<dc:creator>Steffen E Petersen</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC)</dc:title>
<dc:identifier>pmid:37622660</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad578</dc:identifier>
</item>
<item>
<title>2023 ESC Guidelines for the management of cardiomyopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37622657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad194. doi: 10.1093/eurheartj/ehad194. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37622657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37622657</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad194>10.1093/eurheartj/ehad194</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37622657</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Elena Arbelo</dc:creator>
<dc:creator>Alexandros Protonotarios</dc:creator>
<dc:creator>Juan R Gimeno</dc:creator>
<dc:creator>Eloisa Arbustini</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Cristina Basso</dc:creator>
<dc:creator>Connie R Bezzina</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Nico A Blom</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Tim De Winter</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:creator>Marcus Flather</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Kristina H Haugaa</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:creator>Ruxandra Oana Jurcut</dc:creator>
<dc:creator>Sabine Klaassen</dc:creator>
<dc:creator>Giuseppe Limongelli</dc:creator>
<dc:creator>Bart Loeys</dc:creator>
<dc:creator>Jens Mogensen</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Antonis Pantazis</dc:creator>
<dc:creator>Sanjay Sharma</dc:creator>
<dc:creator>J Peter Van Tintelen</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Juan Pablo Kaski</dc:creator>
<dc:creator>ESC Scientific Document Group</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>2023 ESC Guidelines for the management of cardiomyopathies</dc:title>
<dc:identifier>pmid:37622657</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad194</dc:identifier>
</item>
<item>
<title>2023 ESC Guidelines for the management of endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37622656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad193. doi: 10.1093/eurheartj/ehad193. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37622656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37622656</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad193>10.1093/eurheartj/ehad193</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37622656</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Victoria Delgado</dc:creator>
<dc:creator>Nina Ajmone Marsan</dc:creator>
<dc:creator>Suzanne de Waha</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>Margarita Brida</dc:creator>
<dc:creator>Haran Burri</dc:creator>
<dc:creator>Stefano Caselli</dc:creator>
<dc:creator>Torsten Doenst</dc:creator>
<dc:creator>Stephane Ederhy</dc:creator>
<dc:creator>Paola Anna Erba</dc:creator>
<dc:creator>Dan Foldager</dc:creator>
<dc:creator>Emil L Fosbøl</dc:creator>
<dc:creator>Jan Kovac</dc:creator>
<dc:creator>Carlos A Mestres</dc:creator>
<dc:creator>Owen I Miller</dc:creator>
<dc:creator>Jose M Miro</dc:creator>
<dc:creator>Michal Pazdernik</dc:creator>
<dc:creator>Maria Nazarena Pizzi</dc:creator>
<dc:creator>Eduard Quintana</dc:creator>
<dc:creator>Trine Bernholdt Rasmussen</dc:creator>
<dc:creator>Arsen D Ristić</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>Alessandro Sionis</dc:creator>
<dc:creator>Liesl Joanna Zühlke</dc:creator>
<dc:creator>Michael A Borger</dc:creator>
<dc:creator>ESC Scientific Document Group</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>2023 ESC Guidelines for the management of endocarditis</dc:title>
<dc:identifier>pmid:37622656</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad193</dc:identifier>
</item>
<item>
<title>2023 ESC Guidelines for the management of acute coronary syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37622654/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad191. doi: 10.1093/eurheartj/ehad191. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37622654/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37622654</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad191>10.1093/eurheartj/ehad191</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37622654</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Robert A Byrne</dc:creator>
<dc:creator>Xavier Rossello</dc:creator>
<dc:creator>J J Coughlan</dc:creator>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:creator>Alaide Chieffo</dc:creator>
<dc:creator>Marc J Claeys</dc:creator>
<dc:creator>Gheorghe-Andrei Dan</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Mary Galbraith</dc:creator>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>Lynne Hinterbuchner</dc:creator>
<dc:creator>Ewa A Jankowska</dc:creator>
<dc:creator>Peter Jüni</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Vijay Kunadian</dc:creator>
<dc:creator>Margret Leosdottir</dc:creator>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Roberto F E Pedretti</dc:creator>
<dc:creator>Angelos G Rigopoulos</dc:creator>
<dc:creator>Maria Rubini Gimenez</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Pascal Vranckx</dc:creator>
<dc:creator>Sven Wassmann</dc:creator>
<dc:creator>Nanette Kass Wenger</dc:creator>
<dc:creator>Borja Ibanez</dc:creator>
<dc:creator>ESC Scientific Document Group</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>2023 ESC Guidelines for the management of acute coronary syndromes</dc:title>
<dc:identifier>pmid:37622654</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad191</dc:identifier>
</item>
<item>
<title>Long-term Incidence of Ischemic Stroke Following Transient Ischemic Attack: A Nationwide Study During 2014-2020</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37622531/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>Background: The short-term incidence of ischemic stroke after a transient ischemic attack (TIA) is high. However, data on the long-term incidence are not well known but are needed to guide preventive strategies. Methods: Patients with first-time TIA (index date) in the Danish Stroke Registry (January 2014-December 2020) were included and matched 1:4 with individuals from the background population and 1:1 with patients with a first-time ischemic stroke based on age, sex, and calendar year. The...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 25. doi: 10.1161/CIRCULATIONAHA.123.065446. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> The short-term incidence of ischemic stroke after a transient ischemic attack (TIA) is high. However, data on the long-term incidence are not well known but are needed to guide preventive strategies. <b>Methods:</b> Patients with first-time TIA (index date) in the Danish Stroke Registry (January 2014-December 2020) were included and matched 1:4 with individuals from the background population and 1:1 with patients with a first-time ischemic stroke based on age, sex, and calendar year. The incidences of ischemic stroke and mortality from index date were estimated by Aalen-Johansen and Kaplan-Meier estimators, respectively, and compared between groups using multivariable Cox regression. <b>Results:</b> We included 21,500 patients with TIA, 86,000 patients from the background population, and 21,500 patients with ischemic stroke (median age 70.8 years [25th-75th percentile 60.8-78.7]: 53% men). Patients with TIA had more comorbidities than the background population, yet less than the control stroke population. The five-year incidence of ischemic stroke following TIA (6.1% [95% CI 5.7-6.5]) was higher than the background population (1.5% [95%CI 1.4-1.6], hazard ratio (HR) 5.14 [95%CI 4.65-5.69 ]), but lower than the control stroke population (8.9% [95%CI 8.4-9.4], HR 0.58 [95%CI 0.53-0.64]). The five-year mortality for patients with TIA (18.6 % [95%CI 17.9-19.3]) was higher than the background population (14.8% [95%CI 14.5-15.1 ], HR 1.26 [95%CI 1.20-1.32 ]), but lower than the control stroke population (30.1% [95% CI 29.3-30.9), HR 0.41 [95%CI 0.39-0.44]). <b>Conclusions:</b> Patients with first-time TIA had an ischemic stroke incidence of 6.1% during the 5-year follow-up period. Following adjustment for relevant comorbidities, this incidence was approximately five-fold higher than what was found for controls in the background population, and 40% lower than for patients with recurrent ischemic stroke.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37622531/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37622531</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065446>10.1161/CIRCULATIONAHA.123.065446</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37622531</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Naja Emborg Vinding</dc:creator>
<dc:creator>Jawad H Butt</dc:creator>
<dc:creator>Marie Dam Lauridsen</dc:creator>
<dc:creator>Søren Lund Kristensen</dc:creator>
<dc:creator>Søren Paaske Johnsen</dc:creator>
<dc:creator>Johanna Krøll</dc:creator>
<dc:creator>Peter L Graversen</dc:creator>
<dc:creator>Christina Kruuse</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Emil L Fosbøl</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-term Incidence of Ischemic Stroke Following Transient Ischemic Attack: A Nationwide Study During 2014-2020</dc:title>
<dc:identifier>pmid:37622531</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065446</dc:identifier>
</item>
<item>
<title>Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37621213/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 25. doi: 10.1161/CIRCULATIONAHA.123.064556. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37621213/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37621213</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064556>10.1161/CIRCULATIONAHA.123.064556</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37621213</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Rahul Aggarwal</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:creator>Saverio Virdone</dc:creator>
<dc:creator>Sylvie Perreault</dc:creator>
<dc:creator>Ajay K Kakkar</dc:creator>
<dc:creator>Michael G Palazzolo</dc:creator>
<dc:creator>Marc Dorais</dc:creator>
<dc:creator>Gloria Kayani</dc:creator>
<dc:creator>Daniel E Singer</dc:creator>
<dc:creator>Eric Secemsky</dc:creator>
<dc:creator>Jonathan Piccini</dc:creator>
<dc:creator>Usman A Tahir</dc:creator>
<dc:creator>Changyu Shen</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants</dc:title>
<dc:identifier>pmid:37621213</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064556</dc:identifier>
</item>
<item>
<title>Filling An Important Knowledge Gap, The DOAC Score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37621202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 25. doi: 10.1161/CIRCULATIONAHA.123.066316. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37621202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37621202</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066316>10.1161/CIRCULATIONAHA.123.066316</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37621202</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael D Ezekowitz</dc:creator>
<dc:creator>Mohammed Kamareddine</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Filling An Important Knowledge Gap, The DOAC Score</dc:title>
<dc:identifier>pmid:37621202</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066316</dc:identifier>
</item>
<item>
<title>Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37621153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 24. doi: 10.1161/CIRCULATIONAHA.123.065748. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37621153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37621153</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065748>10.1161/CIRCULATIONAHA.123.065748</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37621153</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Cordula Zeller</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Martina Brueckmann</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Muhammad Shariq Usman</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure</dc:title>
<dc:identifier>pmid:37621153</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065748</dc:identifier>
</item>
<item>
<title>Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37619574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This study supports the change in diagnostic category of the ESC/ERS guidelines in a PH population. The newly included patients have an increased mortality independent of significant lung or heart disease. The majority of patients in this new category have underlying heart or lung disease rather than an isolated pulmonary vasculopathy. Mortality is higher if comorbidity is present. Rigorous phenotyping will be pivotal to determine which patients are at risk of progressive...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 24:ehad532. doi: 10.1093/eurheartj/ehad532. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Interventional studies in pulmonary arterial hypertension completed to date have shown to be effective in symptomatic patients with significantly elevated mean pulmonary artery pressure (mPAP) (≥25 mmHg) and pulmonary vascular resistance (PVR) >; 3 Wood Unit (WU). However, in health the mPAP does not exceed 20 mmHg and PVR is 2 WU or lower, at rest. The ESC/ERS guidelines have recently been updated to reflect this. There is limited published data on the nature of these newly defined populations (mPAP 21-24 mmHg and PVR >;2-≤3 WU) and the role of comorbidity in determining their natural history. With the change in guidelines, there is a need to understand this population and the impact of the ESC/ERS guidelines in greater detail.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A retrospective nationwide evaluation of the role of pulmonary haemodynamics and comorbidity in predicting survival among patients referred to the UK pulmonary hypertension (PH) centres between 2009 and 2017. In total, 2929 patients were included in the study. Patients were stratified by mPAP (&lt;21 mmHg, 21-24 mmHg, and ≥25 mmHg) and PVR (≤2 WU, >; 2-≤3 WU, and >;3 WU), with 968 (33.0%) in the mPAP &lt;21 mmHg group, 689 (23.5%) in the mPAP 21-24 mmHg group, and 1272 (43.4%) in the mPAP ≥25 mmHg group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Survival was negatively correlated with mPAP and PVR in the population as a whole. Survival in patients with mildly elevated mPAP (21-24 mmHg) or PVR (>;2-≤3WU) was lower than among those with normal pressures (mPAP &lt;21 mmHg) and normal PVR (PVR ≤ 2WU) independent of comorbid lung and heart disease [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.14-1.61, P = .0004 for mPAP vs. HR 1.28, 95% CI 1.10-1.49, P = .0012 for PVR]. Among patients with mildly elevated mPAP, a mildly elevated PVR remained an independent predictor of survival when adjusted for comorbid lung and heart disease (HR 1.33, 95% CI 1.01-1.75, P = .042 vs. HR 1.4, 95% CI 1.06-1.86, P = .019). 68.2% of patients with a mPAP 21-24 mmHg had evidence of underlying heart or lung disease. Patients with mildly abnormal haemodynamics were not more symptomatic than patients with normal haemodynamics. Excluding patients with heart and lung disease, connective tissue disease was associated with a poorer survival among those with PH. In this subpopulation evaluating those with a mPAP of 21-24 mmHg, survival curves only diverged after 5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study supports the change in diagnostic category of the ESC/ERS guidelines in a PH population. The newly included patients have an increased mortality independent of significant lung or heart disease. The majority of patients in this new category have underlying heart or lung disease rather than an isolated pulmonary vasculopathy. Mortality is higher if comorbidity is present. Rigorous phenotyping will be pivotal to determine which patients are at risk of progressive vasculopathic disease and in whom surveillance and recruitment to studies may be of benefit. This study provides an insight into the population defined by the new guidelines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37619574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37619574</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad532>10.1093/eurheartj/ehad532</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37619574</guid>
<pubDate>Thu, 24 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Nina Karia</dc:creator>
<dc:creator>Luke Howard</dc:creator>
<dc:creator>Martin Johnson</dc:creator>
<dc:creator>David G Kiely</dc:creator>
<dc:creator>James Lordan</dc:creator>
<dc:creator>Colm McCabe</dc:creator>
<dc:creator>Joanna Pepke-Zaba</dc:creator>
<dc:creator>Rose Ong</dc:creator>
<dc:creator>Michael Preiss</dc:creator>
<dc:creator>Daniel Knight</dc:creator>
<dc:creator>Vivek Muthurangu</dc:creator>
<dc:creator>J Gerry Coghlan</dc:creator>
<dc:date>2023-08-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study</dc:title>
<dc:identifier>pmid:37619574</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad532</dc:identifier>
</item>
<item>
<title>Reply: Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):e77. doi: 10.1016/j.jacc.2023.06.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37612018</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.018>10.1016/j.jacc.2023.06.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612018</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jaejin An</dc:creator>
<dc:creator>Yiyi Zhang</dc:creator>
<dc:creator>Andrew E Moran</dc:creator>
<dc:creator>Kristi Reynolds</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</dc:title>
<dc:identifier>pmid:37612018</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.018</dc:identifier>
</item>
<item>
<title>Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37612017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826160715&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 29;82(9):e75-e76. doi: 10.1016/j.jacc.2023.05.068.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37612017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826160715&v=2.17.9.post6+86293ac">37612017</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.068>10.1016/j.jacc.2023.05.068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37612017</guid>
<pubDate>Wed, 23 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Michel Zeitouni</dc:creator>
<dc:creator>Johanne Silvain</dc:creator>
<dc:creator>Jean-Philippe Collet</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:date>2023-08-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</dc:title>
<dc:identifier>pmid:37612017</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.068</dc:identifier>
</item>





























</channel>
</rss>